The University of Southampton
University of Southampton Institutional Repository

The economic cost of congenital CMV in the UK

The economic cost of congenital CMV in the UK
The economic cost of congenital CMV in the UK
Objective: Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital disability. It can disrupt neurodevelopment, causing lifelong impairments including sensorineural hearing loss and developmental delay. This study aimed, for the first time, to estimate the annual economic burden of managing cCMV and its sequelae in the UK.

Design: The study collated available secondary data to develop a static cost model.

Setting: The model aimed to estimate costs of cCMV in the UK for the year 2016.

Patients: Individuals of all ages with cCMV.

Main outcome measures: Direct (incurred by the public sector) and indirect (incurred personally or by society) costs associated with management of cCMV and its sequelae.

Results: The model estimated that the total cost of cCMV to the UK in 2016 was £732 million (lower and upper estimates were between £495 and £942 million). Approximately 40% of the costs were directly incurred by the public sector, with the remaining 60% being indirect costs, including lost productivity. Long-term impairments caused by the virus had a higher financial burden than the acute management of cCMV.

Conclusions: The cost of cCMV is substantial, predominantly stemming from long-term impairments. Costs should be compared against investment in educational strategies and vaccine development programmes that aim to prevent virus transmission, as well as the value of introducing universal screening for cCMV to both increase detection of children who would benefit from treatment, and to build a more robust evidence base for future research.
0003-9888
Retzler, Jenny
55c3a926-016b-4003-84ec-ba39e8edda93
Hex, Nick
6994714c-9848-4e7f-b2ad-fa6402394fa8
Bartlett, Chris
08188802-1914-436e-9945-9acde9b3afa8
Webb, Anne
00bd1fad-0880-4b1f-9802-d64dfdba9ae3
Wood, Sharon
abc82a05-baa6-4a8c-ad7e-9982b854643c
Star, Caroline
6c77cbfa-699d-47a1-a8d5-d0bbef7e86a6
Griffiths, Paul
bf1dfc3d-551e-4ea0-b763-6f7010e96b7f
Jones, Christine E.
48229079-8b58-4dcb-8374-d9481fe7b426
Retzler, Jenny
55c3a926-016b-4003-84ec-ba39e8edda93
Hex, Nick
6994714c-9848-4e7f-b2ad-fa6402394fa8
Bartlett, Chris
08188802-1914-436e-9945-9acde9b3afa8
Webb, Anne
00bd1fad-0880-4b1f-9802-d64dfdba9ae3
Wood, Sharon
abc82a05-baa6-4a8c-ad7e-9982b854643c
Star, Caroline
6c77cbfa-699d-47a1-a8d5-d0bbef7e86a6
Griffiths, Paul
bf1dfc3d-551e-4ea0-b763-6f7010e96b7f
Jones, Christine E.
48229079-8b58-4dcb-8374-d9481fe7b426

Retzler, Jenny, Hex, Nick, Bartlett, Chris, Webb, Anne, Wood, Sharon, Star, Caroline, Griffiths, Paul and Jones, Christine E. (2018) The economic cost of congenital CMV in the UK. Archives of Disease in Childhood. (doi:10.1136/archdischild-2018-316010).

Record type: Article

Abstract

Objective: Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital disability. It can disrupt neurodevelopment, causing lifelong impairments including sensorineural hearing loss and developmental delay. This study aimed, for the first time, to estimate the annual economic burden of managing cCMV and its sequelae in the UK.

Design: The study collated available secondary data to develop a static cost model.

Setting: The model aimed to estimate costs of cCMV in the UK for the year 2016.

Patients: Individuals of all ages with cCMV.

Main outcome measures: Direct (incurred by the public sector) and indirect (incurred personally or by society) costs associated with management of cCMV and its sequelae.

Results: The model estimated that the total cost of cCMV to the UK in 2016 was £732 million (lower and upper estimates were between £495 and £942 million). Approximately 40% of the costs were directly incurred by the public sector, with the remaining 60% being indirect costs, including lost productivity. Long-term impairments caused by the virus had a higher financial burden than the acute management of cCMV.

Conclusions: The cost of cCMV is substantial, predominantly stemming from long-term impairments. Costs should be compared against investment in educational strategies and vaccine development programmes that aim to prevent virus transmission, as well as the value of introducing universal screening for cCMV to both increase detection of children who would benefit from treatment, and to build a more robust evidence base for future research.

Text
AuthorAccepted_cCMV - Accepted Manuscript
Download (64kB)

More information

Accepted/In Press date: 12 November 2018
e-pub ahead of print date: 24 November 2018

Identifiers

Local EPrints ID: 426413
URI: http://eprints.soton.ac.uk/id/eprint/426413
ISSN: 0003-9888
PURE UUID: 9d6d580e-c446-451f-b0bf-567340b7d029
ORCID for Christine E. Jones: ORCID iD orcid.org/0000-0003-1523-2368

Catalogue record

Date deposited: 27 Nov 2018 17:30
Last modified: 16 Mar 2024 04:28

Export record

Altmetrics

Contributors

Author: Jenny Retzler
Author: Nick Hex
Author: Chris Bartlett
Author: Anne Webb
Author: Sharon Wood
Author: Caroline Star
Author: Paul Griffiths

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×